Phathom Pharmaceuticals, Inc. Common Stock

PHATNASDAQ • USD
5.74 USD
↘ 0.48 (7.72%)AT CLOSE (03:59 PM EST)
5.81
↗ 0.07 (1.15%)
POST MARKET (AS OF 04:15 PM EDT)
Post Market
AS OF 04:15 PM EDT
5.81
↗ 0.07 (1.15%)
🔴Market: CLOSED

PHAT is currently priced at $5.74. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, exceptional Return on Equity (23.9%), a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest PHAT is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Oct 30, 2026.

Open?$6.32
High?$6.32
Low?$5.59
Prev. Close?$6.22
Volume?1.6M
Avg. Volume?1.6M
VWAP?$5.81
Rel. Volume?1.04x
Bid / Ask
Bid?$5.76 × 100
Ask?$5.85 × 600
Spread?$0.09
Midpoint?$5.81
Valuation & Ratios
Market Cap?466.6M
Shares Out?80.9M
Float?56.0M
Float %?69.3%
P/E Ratio?N/A
P/B Ratio?-1.34
EPS?-$1.02
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Employees
371
Market Cap
466.6M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2019-10-25
Address
100 CAMPUS DRIVE,
FLORHAM PARK, NJ 07932
Phone: (877) 742-8466
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
0
Momentum?
83
Short Sent.?
45
Piotroski F-Score?3/9Weak
Altman Z-Score?-4.85Distress
Confidence?51%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?17.46%High
Short Interest?9.8M
Days to Cover?6.9
Free Float56.0M
Avg Daily Volume1.4M
Settlement Date2026-10-15
Financial Health
Current Ratio?1.76Adequate
Quick Ratio?1.72Adequate
Cash Ratio?1.06Strong
Debt/Equity?-0.48Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
S&P
97
-1.34CHEAP▾
P/S?
Peers
100
S&P
74
1.70CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-18.0CHEAP▾
EV/Sales?
Peers
100
S&P
82
1.63CHEAP▾
Returns & Efficiency
ROE?
Peers
50
S&P
72
23.9%STRONG▾
ROA?
S&P
3
-24.1%WEAK▾
Cash Flow & Enterprise
FCF?$-21041000
Enterprise Value?$449.0M
Fundamentals ratios updated end of day